Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial

References

• Fashner J, Bell AL. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician 2011; 83(12):1432-7; PMID:21671543.
   PubMed Web of Science ®Google Scholar
• Cohen JI. VZV: molecular basis of persistence (latency and reactivation). In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, eds. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press 2007, 2007.
   Google Scholar
• Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpaa ML, McKendrick MW, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44(Suppl 1):S1-26; PMID:17143845; http://dx.doi.org/10.1086/510206
   PubMed Web of Science ®Google Scholar
• Lee BW. Review of varicella zoster seroepidemiology in India and Southeast Asia. Trop Med Int Health 1998; 3(11):886-90; PMID:9855401; http://dx.doi.org/10.1046/j.1365-3156.1998.00316.x
   PubMed Web of Science ®Google Scholar
• Kilgore PE, Kruszon-Moran D, Seward JF, Jumaan A, Van Loon FP, Forghani B, McQuillan GM, Wharton M, Fehrs LJ, Cossen CK, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003; 70(Suppl 1):S111-8; PMID:12627498; http://dx.doi.org/10.1002/jmv.10364
   PubMedGoogle Scholar
• Araujo LQ, Macintyre CR, Vujacich C. Epidemiology and burden of herpes zoster and post-herpetic neuralgia in Australia, Asia and South America. Herpes 2007; 14(Suppl 2):40-4; PMID:17939895.
   PubMedGoogle Scholar
• Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I, Rota MC, de Melker H, Mossong J, Slacikova M, et al. The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 2007; 25(45):7866-72; PMID:17919788; http://dx.doi.org/10.1016/j.vaccine.2007.07.036
   PubMed Web of Science ®Google Scholar
• Tseng HF, Chi M, Smith N, Marcy SM, Sy LS, Jacobsen SJ. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis 2012; 206(2):190-6; PMID:22669900; http://dx.doi.org/10.1093/infdis/jis334
   PubMed Web of Science ®Google Scholar
• Weitzman D, Shavit O, Stein M, Cohen R, Chodick G, Shalev V. A population based study of the epidemiology of Herpes Zoster and its complications. J Infect 2013; 67(5):463-9; PMID:23872209; http://dx.doi.org/10.1016/j.jinf.2013.06.016
   PubMed Web of Science ®Google Scholar
• Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc 2011; 86(2):88-93; PMID:21220354; http://dx.doi.org/10.4065/mcp.2010.0618
   PubMed Web of Science ®Google Scholar
• Volpi A, Gatti A, Pica F. Frequency of herpes zoster recurrence. Mayo Clin Proc 2011; 86(6):586; author reply -7; PMID:21628622; http://dx.doi.org/10.4065/mcp.2011.0096
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barbera J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016; 375(11):1019-32; PMID:27626517; http://dx.doi.org/10.1056/NEJMoa1603800
   Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barbera J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372(22):2087-96; PMID:25916341; http://dx.doi.org/10.1056/NEJMoa1501184
   PubMed Web of Science ®Google Scholar
• Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age. J Infect Dis 2013; 208(12):1953-61; PMID:23904292; http://dx.doi.org/10.1093/infdis/jit365
   PubMed Web of Science ®Google Scholar
• Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, Plassmann G, Schwarz TF, Ledent E, Heineman TC. Safety and immunogenicity of 3 different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine 2014; 32(15):1745-53; PMID:24508036; http://dx.doi.org/10.1016/j.vaccine.2014.01.019
   PubMed Web of Science ®Google Scholar
• Berkowitz EM, Moyle G, Stellbrink HJ, Schurmann D, Kegg S, Stoll M, El Idrissi M, Oostvogels L, Heineman TC. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis 2015; 211(8):1279-87; PMID:25371534.
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Sullivan KM, Marty FM, Dadwal SS, Papanicolaou GA, Shea TC, Mossad SB, Andreadis C, Young JA, Buadi FK, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood 2014; 124(19):2921-9; PMID:25237196; http://dx.doi.org/10.1182/blood-2014-04-573048
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapeliere P, Vassilev V, Ledent E, Heineman TC. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 2012; 206(8):1280-90; PMID:22872734; http://dx.doi.org/10.1093/infdis/jis497
   PubMed Web of Science ®Google Scholar
• Garcon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011; 10(4):471-86; PMID:21506645; http://dx.doi.org/10.1586/erv.11.29
   PubMed Web of Science ®Google Scholar
• Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014; 4(6):e004833; PMID:24916088; http://dx.doi.org/10.1136/bmjopen-2014-004833
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352(22):2271-84; PMID:15930418; http://dx.doi.org/10.1056/NEJMoa051016
   PubMed Web of Science ®Google Scholar